Bacillus sp. NRC5 is a new strain that grows in Egyptian beaches. This strain produces acidic exo-
polysaccharide that have excellent
antioxidant, anti-inflammatory and anti-
tumor properties. The current study aimed to introduce a new
natural product feasible for
prostate cancer therapies. The anti-
prostate cancer of acidic exo-
polysaccharide produced from marine Bacillus sp. NRC5 (EBPS) was determined using 7,12-dimethylbenz-(a)-
anthracene; DMBA-induced
prostate cancer in male Sprague Dawley rats. Rats were subcutaneously injected with
testosterone (3 mg/kg/day for 3 months) and a single dose of DMBA (65 mg/kg) for induction of
prostate cancer. EBPS was administrated orally at dose 200 mg/kg/day for 3 months. To study protective effect of EBPS, animals received EBPS before
cancer induction, meanwhile in
therapeutic effect animals received EBPS after
cancer induction. EBPS debug oxidative stress and inflammatory conditions associated with
prostate cancer. EBPS either protective or therapeutic material considerably reduced
cancer growth rate-limiting
enzyme-i.e., 5-α-reductase (46.89 ± 1.72 and 44.86 ± 2.56 µg Eq/mL) and Na+/K+
ATPase (0.44 ± 0.03 and 0.42 ± 0.02 µg Eq/mL), compared to
cancer control (69.68 ± 3.46 µg Eq/mL). In addition, both
cancer biomarkers-i.e.,
prostate-specific antigen and
carcinoembryonic antigen were significantly lowered as evidence of the ability of EBPS to protect and treat
prostate cancer in chemically induced rats. EBPS showed protective and therapeutic efficacy on
testosterone-DMBA-induced
prostate cancer rats with a good safety margin. This study may go to clinical trials after a repeated study on another type of small experimental animal, their offspring, and one big experimental animal.